deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02207530

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Sponsor: AstraZeneca

Conditions Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck
Interventions MEDI4736
Updated 20 times since 2017 Last updated: Sep 11, 2020 Started: Oct 23, 2014 Primary completion: Sep 26, 2016 Completion: Jul 6, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 20 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Apr 2018 · 4 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Mar 2019 · 5 months · monthly snapshot~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 15 earlier versions

  1. Aug 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE2

  2. Jun 2020 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2

  3. Mar 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE2

  4. Nov 2019 — Mar 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2019 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2019 — Sep 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Mar 2019 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Oct 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  9. Jul 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  11. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  12. Dec 2017 — Apr 2018 [monthly]

    Active Not Recruiting PHASE2

  13. Jun 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE2

  14. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE2

  15. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • PRA Health Sciences
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France , Ann Arbor, United States , Augusta, United States , Austin, United States , Baltimore, United States , Barakaldo, Spain , Barcelona, Spain , Batumi, Georgia , Berlin, Germany , Birmingham, United Kingdom and 87 more locations